Texas Permanent School Fund Boosts Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Texas Permanent School Fund grew its position in Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) by 0.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,833 shares of the life sciences company’s stock after buying an additional 191 shares during the quarter. Texas Permanent School Fund owned 0.06% of Integra LifeSciences worth $2,801,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Steward Partners Investment Advisory LLC lifted its stake in shares of Integra LifeSciences by 73.7% during the 1st quarter. Steward Partners Investment Advisory LLC now owns 707 shares of the life sciences company’s stock worth $45,000 after purchasing an additional 300 shares during the last quarter. First Horizon Advisors Inc. acquired a new position in Integra LifeSciences during the 2nd quarter valued at about $54,000. Covestor Ltd increased its position in Integra LifeSciences by 63.0% during the 1st quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock valued at $100,000 after buying an additional 602 shares in the last quarter. Captrust Financial Advisors increased its position in Integra LifeSciences by 95.0% during the 1st quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock valued at $129,000 after buying an additional 976 shares in the last quarter. Finally, Parametrica Management Ltd acquired a new position in Integra LifeSciences during the 1st quarter valued at about $215,000. 87.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IART has been the topic of several recent analyst reports. StockNews.com initiated coverage on Integra LifeSciences in a research report on Wednesday, October 12th. They set a “buy” rating on the stock. Citigroup dropped their target price on Integra LifeSciences from $57.00 to $50.00 in a report on Wednesday, October 5th. Truist Financial lowered their price target on Integra LifeSciences from $60.00 to $46.00 and set a “hold” rating on the stock in a research report on Monday, October 17th. Morgan Stanley increased their price target on Integra LifeSciences from $49.00 to $50.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 27th. Finally, Jefferies Financial Group assumed coverage on Integra LifeSciences in a research note on Tuesday, October 11th. They issued a “hold” rating and a $48.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $57.38.

Integra LifeSciences Stock Up 2.4 %

Shares of NASDAQ IART opened at $53.46 on Friday. The stock has a market cap of $4.46 billion, a PE ratio of 25.95, a price-to-earnings-growth ratio of 1.47 and a beta of 1.17. The company has a quick ratio of 2.91, a current ratio of 3.93 and a debt-to-equity ratio of 0.86. Integra LifeSciences Holdings Co. has a 52-week low of $40.67 and a 52-week high of $71.03. The business has a 50-day moving average price of $46.02 and a 200 day moving average price of $52.71.

Integra LifeSciences Company Profile

(Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

Featured Articles

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.